• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Politics and its intersection with coverage with evidence development: a qualitative analysis from expert interviews.政治及其与循证决策覆盖的交织:专家访谈的定性分析。
BMC Health Serv Res. 2013 Mar 9;13:88. doi: 10.1186/1472-6963-13-88.
2
Coverage with evidence development for pharmaceuticals: a policy in evolution?药品的证据开发覆盖范围:不断演变的政策?
Int J Health Serv. 2011;41(2):337-54. doi: 10.2190/HS.41.2.h.
3
Coverage with evidence development: an examination of conceptual and policy issues.基于证据生成的覆盖范围:概念与政策问题审视
Int J Technol Assess Health Care. 2007 Fall;23(4):425-32. doi: 10.1017/S0266462307070651.
4
The use of evidence to guide decision-making during the COVID-19 pandemic: divergent perspectives from a qualitative case study in British Columbia, Canada.利用证据在 COVID-19 大流行期间指导决策:来自加拿大不列颠哥伦比亚省的定性案例研究的不同观点。
Health Res Policy Syst. 2024 Jun 3;22(1):66. doi: 10.1186/s12961-024-01146-2.
5
'The problem is small enough, the problem is big enough': a qualitative study of health technology assessment and public policy on drug funding decisions for children.“问题虽小,却也重大”:儿童药物资金决策的卫生技术评估和公共政策的定性研究。
Int J Equity Health. 2020 Mar 30;19(1):45. doi: 10.1186/s12939-020-01164-w.
6
Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.避免和识别健康技术评估模型中的错误:定性研究和方法学综述。
Health Technol Assess. 2010 May;14(25):iii-iv, ix-xii, 1-107. doi: 10.3310/hta14250.
7
The evidence-policy divide: a 'critical computational linguistics' approach to the language of 18 health agency CEOs from 9 countries.证据-政策鸿沟:一种“关键计算语言学”方法,分析来自 9 个国家的 18 位卫生机构首席执行官的语言。
BMC Public Health. 2012 Oct 30;12(1):932. doi: 10.1186/1471-2458-12-932.
8
Political Architecture And Legal Framework Related To Social Health Protection Schemes In Pakistan: Qualitative Inquiry Of Policy Makers' Viewpoint.巴基斯坦社会健康保护计划的政治架构与法律框架:政策制定者观点的定性探究
J Ayub Med Coll Abbottabad. 2018 Jul-Sep;30(3):389-396.
9
Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.超越黑木树:影响澳大利亚地区、农村和偏远地区的健康研究问题的快速综述。
Med J Aust. 2020 Dec;213 Suppl 11:S3-S32.e1. doi: 10.5694/mja2.50881.
10
The use of economic evaluations in NHS decision-making: a review and empirical investigation.国民健康服务体系决策中经济评估的应用:一项综述与实证研究
Health Technol Assess. 2008 Apr;12(7):iii, ix-x, 1-175. doi: 10.3310/hta12070.

引用本文的文献

1
Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making.欧洲药物研发利益相关者对治疗优化及其在决策中应用潜力的看法。
Front Pharmacol. 2020 Feb 5;11:43. doi: 10.3389/fphar.2020.00043. eCollection 2020.
2
Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends.欧盟的风险分担协议:主要趋势的系统综述
Pharmacoecon Open. 2018 Jun;2(2):109-123. doi: 10.1007/s41669-017-0044-1.
3
The Australian Managed Entry Scheme: Are We Getting it Right?澳大利亚管理准入计划:我们做对了吗?
Pharmacoeconomics. 2018 May;36(5):555-565. doi: 10.1007/s40273-018-0633-6.
4
A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma.澳大利亚证据生成覆盖范围的一个实际例子——伊匹单抗治疗转移性黑色素瘤。
J Pharm Policy Pract. 2018 Feb 13;11:4. doi: 10.1186/s40545-018-0131-4. eCollection 2018.
5
Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis.药物批准状态及列入公共处方集的建议:一项加拿大队列分析。
BMJ Open. 2017 Oct 22;7(10):e018372. doi: 10.1136/bmjopen-2017-018372.
6
Health technology assessment in Switzerland: a descriptive analysis of "Coverage with Evidence Development" decisions from 1996 to 2013.瑞士的卫生技术评估:对1996年至2013年“有证据支持的覆盖范围”决策的描述性分析
BMJ Open. 2015 Mar 27;5(3):e007021. doi: 10.1136/bmjopen-2014-007021.
7
Living laboratory: whole-genome sequencing as a learning healthcare enterprise.活体实验室:作为学习型医疗企业的全基因组测序
Clin Genet. 2015 Apr;87(4):311-8. doi: 10.1111/cge.12461. Epub 2014 Sep 6.

本文引用的文献

1
Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.为 NICE 何时应仅在适当设计的证据开发计划背景下推荐使用卫生技术制定决策框架提供信息。
Health Technol Assess. 2012;16(46):1-323. doi: 10.3310/hta16460.
2
Coverage with evidence development for pharmaceuticals: a policy in evolution?药品的证据开发覆盖范围:不断演变的政策?
Int J Health Serv. 2011;41(2):337-54. doi: 10.2190/HS.41.2.h.
3
Commentary: Scheme has benefited patients.评论:该方案已使患者受益。
BMJ. 2010 Jun 3;340:c2707. doi: 10.1136/bmj.c2707.
4
Multiple sclerosis risk sharing scheme: a costly failure.多发性硬化症风险分担计划:代价高昂的失败。
BMJ. 2010 Jun 3;340:c1672. doi: 10.1136/bmj.c1672.
5
Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review.行业关联与罗格列酮心血管风险立场之间的关联:横断面系统性综述。
BMJ. 2010 Mar 18;340:c1344. doi: 10.1136/bmj.c1344.
6
Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis.肺动脉高压的药物治疗:系统评价和荟萃分析。
Respir Res. 2010 Jan 29;11(1):12. doi: 10.1186/1465-9921-11-12.
7
Access with evidence development: the US experience.循证准入:美国经验。
Pharmacoeconomics. 2010;28(2):153-62. doi: 10.2165/11531050-000000000-00000.
8
Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.为无法资助的项目提供资金:在将新技术和创新技术引入医疗保健系统的决策中管理不确定性的机制。
Pharmacoeconomics. 2010;28(2):113-42. doi: 10.2165/11530820-000000000-00000.
9
Principles of design of access with evidence development approaches: a consensus statement from the Banff Summit.采用循证发展方法的获取设计原则:班夫峰会共识声明
Pharmacoeconomics. 2010;28(2):109-11. doi: 10.2165/11530860-000000000-00000.
10
We know accurately only when we know little.仅当我们所知甚少时,我们才确切地知道。
Pharmacoeconomics. 2010;28(2):105-7. doi: 10.2165/11531510-000000000-00000.

政治及其与循证决策覆盖的交织:专家访谈的定性分析。

Politics and its intersection with coverage with evidence development: a qualitative analysis from expert interviews.

机构信息

Graduate Program in Health, York University, Toronto, Canada.

出版信息

BMC Health Serv Res. 2013 Mar 9;13:88. doi: 10.1186/1472-6963-13-88.

DOI:10.1186/1472-6963-13-88
PMID:23497271
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3599546/
Abstract

BACKGROUND

Pressures on health care budgets have led policy makers to discuss how to balance the provision of costly technologies to populations in need and making coverage decisions under uncertainty. Coverage with evidence development (CED) is being employed to meet these challenges.

METHODS

Twenty-four interviews were carried out between June 2009 and December 2010 with researchers, decision makers and policy makers from Australia, Canada, United Kingdom and United States. Three phases of coding occurred, the first being manual coding where the interviews were read and notes were taken and nodes were extracted and imputed. NVIVO coding was applied to the interview transcripts, with both broad general searches for word usages and imputed nodes.

RESULTS

Four overarching thematic areas emerged out of contextual analysis of the interviews - (1) what constitutes CED; (2) the lack of a systematic approach/governance structure; (3) the role of the pharmaceutical industry and overt political considerations in CED; and (4) alternatives and barriers to CED. We explore these themes and then use concrete examples of CED projects in each of the four countries to illustrate the political issues that our interviewees raised.

CONCLUSION

Until the underlying political nature of CED is recognized then fundamental questions about its usefulness and operation will remain unresolved.

摘要

背景

医疗保健预算的压力促使政策制定者讨论如何在为有需要的人群提供昂贵技术和在不确定的情况下做出覆盖决策之间取得平衡。证据开发覆盖(CED)正在被用来应对这些挑战。

方法

2009 年 6 月至 2010 年 12 月期间,与来自澳大利亚、加拿大、英国和美国的研究人员、决策者和政策制定者进行了 24 次访谈。进行了三个阶段的编码,第一阶段是手动编码,阅读访谈并记录笔记,提取和推断节点。对访谈记录进行了 NVIVO 编码,同时进行了广泛的通用词汇搜索和推断节点搜索。

结果

通过对访谈的语境分析,出现了四个总体主题领域 - (1) CED 的构成;(2) 缺乏系统的方法/治理结构;(3) 制药行业和 CED 中明显的政治考虑因素的作用;以及 (4) CED 的替代方案和障碍。我们探讨了这些主题,然后使用来自四个国家的 CED 项目的具体例子来说明我们的受访者提出的政治问题。

结论

除非认识到 CED 的潜在政治性质,否则关于其有用性和运作的基本问题将仍然没有得到解决。